Audax Medical was granted an exclusive worldwide license from Northeastern University (NU) for a self-assembling, arginine-rich nanomolecule for development in tissue regeneration.
The nanomolecule was developed in Dr. Thomas Webster’s Nanomedicine Lab in NU’s Department of Chemical Engineering. Initial tests indicate the potential to accelerate healing and promote targeted cell functions, while limiting inflammation and infection. Notably, the nanoparticles inhibit bacteria without the use of antibiotics.
Audax seeks to develop the technology for applications in orthopaedics, spine, wound care, etc. In 2010, the company acquired exclusive rights to Arxis osteobiologic nanotechnology, under development for regeneration of bone, cartilage and other soft tissues.
Sources: Audax Medical, Inc.; ORTHOWORLD Inc.
Audax Medical was granted an exclusive worldwide license from Northeastern University (NU) for a self-assembling, arginine-rich nanomolecule for development in tissue regeneration.
The nanomolecule was developed in Dr. Thomas Webster's Nanomedicine Lab in NU's Department of Chemical Engineering. Initial tests indicate the potential to...
Audax Medical was granted an exclusive worldwide license from Northeastern University (NU) for a self-assembling, arginine-rich nanomolecule for development in tissue regeneration.
The nanomolecule was developed in Dr. Thomas Webster’s Nanomedicine Lab in NU’s Department of Chemical Engineering. Initial tests indicate the potential to accelerate healing and promote targeted cell functions, while limiting inflammation and infection. Notably, the nanoparticles inhibit bacteria without the use of antibiotics.
Audax seeks to develop the technology for applications in orthopaedics, spine, wound care, etc. In 2010, the company acquired exclusive rights to Arxis osteobiologic nanotechnology, under development for regeneration of bone, cartilage and other soft tissues.
Sources: Audax Medical, Inc.; ORTHOWORLD Inc.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.